8.2 Malignant disease

8.2.1 Antibody responsive malignancy

All drugs in this section are classified as RED in the TLS unless otherwise indicated below

Monoclonal Antibodies (Antineoplastic)

Atezolizumab (parenteral)

• NICE TA520 Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy carcinoma after platinum-containing chemotherapy
• NICE TA525 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
• NICE TA584 Atezolizumab for treating metastatic non-squamous non-small-cell lung cancer
• NICE TA638 Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
• NICE TA639 Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
• NICE TA666 Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
• NICE TA705 Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
• NICE TA739 Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable
• NICE TA823 Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
• NHSE SSC 2560 New Subcutaneous formulation for atezolizumab 1875mg

Avelumab (parenteral)

• NICE TA517 Avelumab for treating metastatic Merkel cell carcinoma as per Cancer Drug Fund
• NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma
• NICE TA691 Avelumab for untreated metastatic Merkel cell carcinoma
• NICE TA788 Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy

Bevacizumab (parenteral)

• As per Cancer Drugs Fund restrictions

Bevacizumab (intravitreal)

• Unlicensed use - refer to chapter 11 for criteria based access policies

Blinatumomab

• NICE TA450 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
• NICE TA589 - Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity

Brentuximab (parenteral)

• NICE TA452 (replaces TA446) Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma as per Cancer Drugs Fund
• NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
• NICE TA577 Brentuximab vedotin for treating CD-30 positive cutaneous T-cell lymphoma
• NICE TA641 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma

Caplacizumab (parenteral)

• NICE TA667 Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura

Cetuximab (parenteral)

• NICE TA439 guidance Colorectal
• NICE TA145 guidance Head and neck
• NICE TA473 guidance Recurrent or metastatic squamous cell cancer of the head and neck

Cemiplimab (parenteral)

• NICE TA802 Cemiplimab for treating advanced cutaneous squamous cell carcinoma

Daratumumab (parenteral)

• NICE TA897 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
• NICE TA763 Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable
• NICE TA783 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
• NICE TA917 Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
• NICE TA959 Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis

Dinutuximab beta (parenteral)

• NICE TA538 Dinutuximab beta for treating neuroblastoma

Dostarlimab

• NICE TA779 Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
• NHSE SSC 2534 Dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy
• NICE TA963 Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Durvalumab (parenteral)

• NICE TA798 Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation
• NICE TA944 Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer

Elranatamab

• NHSE SSC 2670 Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

Epcoritamab

• NICE TA954 Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

Gemtuzumab ozogamicin (parenteral)

• NICE TA545 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia

Glofitamab

• NICE TA927 Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

Inotuzumab ozogamicin (parenteral)

• NICE TA541 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

Ipilimumab (parenteral)

• NICE TA268 Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
• NICE TA319 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
• NICE TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma
• NICE TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
• NICE TA716 Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
• NICE TA724 Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer

Isatuximab (parenteral)

• NICE TA658 Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

Loncastuximab tesirine

• NICE TA947 Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments

Mogamulizumab

• NICE TA754 Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome

Nivolumab (parenteral)

• NICE TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma
• NICE TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma
• NICE TA417 for previously treated advanced renal cell carcinoma
• NICE TA462 for treating relapsed or refractory classical Hodgkin lymphoma
• Early Access to Medicines Scheme NHS England SSC 1611 – Treatment as monotherapy of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adult patients whose tumours express programmed death ligand-1 (PD-L1)
• Early Access to Medicines Scheme NHS England SSC 1612 - Treatment as monotherapy of adult patients with advanced renal cell carcinoma after prior therapy
• NICE TA655 Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
• NICE TA684 Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
• NICE TA707 Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
• NICE TA713 Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
• NICE TA716 Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
• NICE TA724 Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer
• NICE TA736 Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
• NICE TA746 Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer
• NICE TA780 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
• NICE TA817 Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence
• NICE TA818 Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
• NICE TA865 Nivolumab with fluoropyrimidine and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
• NICE TA857 Nivolumab with platinum and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
• NICE TA876 Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
• NICE TA950 Nivolumab–Relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over

Obinutuzumab (parenteral)

• NICE TA343 Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
• NICE TA513 Obinutuzumab for untreated advanced follicular lymphoma
• NICE TA629 Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
• NHSE SSC 2579 Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab

Panitumumab (parenteral)

• NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer

Pembrolizumab (parenteral)

• NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
• NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab
• NICE TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy. As per conditions in NHS England Circular SSC 1709
• NICE TA531 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (CDF)
• NICE TA540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma. As per Cancer Drug Fund restrictions
• NICE TA661 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
• NICE TA674 
• NICE TA683 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
• NICE TA692 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
• NICE TA709 Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
• NICE TA737 Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
• NICE TA766 Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma
• NICE TA770 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
• NICE TA772 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies
• NICE TA801 Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
• NICE TA830 Pembrolizumab for adjuvant treatment of renal cell carcinoma
• NICE TA837 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma
• NICE TA851 Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer
• NICE TA904 Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
• NICE TA914 Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
• NICE TA939 Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
• NHSE SSC 2631 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over

Pertuzumab (parenteral)

• NICE TA424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
• NICE TA509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
• NICE TA569 Pertuzumab for adjuvant treatment of HER2-positive early-stage breast cancer

Polatuzumab vedotin (parenteral)

• NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
• NICE TA874 Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma

Ravulizumab

• NICE TA710 Ravulizumab for treating atypical haemolytic uraemic syndrome

Rituximab (parenteral)

• NICE TA195 guidance Rheumatoid Arthritis - drugs for treatment after failure of a TNF inhibitor
• NICE TA243 guidance for the first-line treatment of stage III-IV follicular lymphoma
• NICE TA226 guidance for the treatment of follicular non-Hodgkin’s lymphoma (maintenance treatment following response to first line chemotherapy)
• NICE TA137 guidance for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
• NICE TA174 guidance for the first-line treatment of chronic lymphocytic leukaemia
• NICE TA193 guidance for the treatment of relapsed chronic lymphocytic leukaemia
• NICE TA308 guidance Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
• For ABO incompatible Kidney transplants according to NBT protocol (NBT Renal Policy)
• For acquired haemophilia- NHS England Policy F02/P/a
• For ANCA-associated vasculitis in adults see NHS England Policy A13/P/a Rituximab for the treatment of ANCA-associated vasculitis in adults
• For the treatment of immune thrombocytopenic purpura (ITP) Treatment in accordance with BNSSG ITP pathway
• For the treatment of Autoimmune haemolytic anaemia. See http://www.b-s-h.org.uk/media/2636/aiha_primary_guideline_bsh_website.pdf
• NHSE SSC 2433 Rituximab in the management of Thrombotic Thrombocytopenic Purpura (TTP)
• For immunoglobulin G4-related disease (IgG4-RD) see NHSE policy 16057/P
• For cytopenia complicating primary immunodeficiency, as per NHSE policy 16044/P
• For Immunobullous disease, as per NHSE policy 16035/P
• Rituximab and eculizumab for delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies as per NHS England Specialised Commissioning Policy
• Rituximab used as an addition to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia as per the NHS England Specialised Commissioning Policy
• Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and post-pubescent children as per NHSE Clinical Commissioning Policy
• Rituximab for idiopathic membranous nephropathy (Adults) as per NHSE Clinical Commissioning Policy
• Rituximab for second line treatment for anti-NMDAR autoimmune encephalitis NHSE Clinical Commissioning Policy
• Rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults as per NHSE Clinical Commissioning Policy
• Rituximab for Neuromyelitis optica as per Commissioning Policy

Rituximab biosimilar (parenteral)

• For myasthenia gravis as per NHSE policy 170084P

Sacituzumab govitecan

• NICE TA819 Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies

Trastuzumab (parenteral)

• NICE TA34 on the use of trastuzumab for the treatment of advanced breast cancer
• NICE NG101 Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
• NICE TA208 Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
• NICE TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
• NICE TA509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
• NICE TA632 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
• NICE TA704 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
• NICE TA862 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments

8.2.2 Cytotoxic responsive malignancy

Alkylating Agents

Bendamustine (parenteral)

• NICE TA216 guidance Bendamustine for the first-line treatment of chronic lymphocytic leukaemia

Busulfan (Busulphan) (oral & parenteral)

Carmustine implant (parenteral) (Glidael^®)

• NICE TA121 guidance Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
• Parenteral – unlicensed as part of ‘BEAM’ conditioning in adult BMT patients

Chlorambucil (oral)

Cyclophosphamide (oral & parenteral)

• TLS Red for malignant conditions

Dacarbazine (parenteral)

Ifosfamide (parenteral)

Lomustine (oral)

Melphalan (oral & parenteral)

Thiotepa (parenteral)

Temozolomide (oral)

• Temozolomide as adjuvant treatment for people with newly diagnosed anaplastic astrocytoma without 1p/19q codeletion following surgery and radiotherapy as per NHSE commissioning policy

Treosulfan (parenteral)

• NICE TA640 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant

Anthracyclines

Daunorubicin (parenteral)

• NICE TA552 Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia

Doxorubicin (parenteral)

Doxorubicin, pegylated liposomal (parenteral)

• NICE TA389 guidance Recurrent ovarian cancer

Epirubicin (parenteral)

Idarubicin (oral)

Mitoxantrone (parenteral)

Pixantrone (parenteral)

• NICE TA306 Pixantrone monotherapy for treating multiple relapsed or refractory aggressive non-Hodgkin's B cell lymphoma

Antimetabolites

Azacitidine

• NICE TA218 Parenteral azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
• NICE TA827 Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy

Capecitabine (oral)

• NICE TA191 guidance Capecitabine for the treatment of advanced gastric cancer
• NICE TA100 guidance Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer
• NICE TA61 guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
• NICE CG81 Advanced breast cancer (update): Diagnosis and treatment

Cladribine (parenteral)

Clofarabine (parenteral)

• As per Cancer Drugs Fund restrictions
• As per NHSE clinical commissioning policy 170080P Clofarabine for refractory or relapsed acute myeloid leukaemia as a bridge to stem cell transplantation: No new patients from 7th January 2019

Cytarabine (parenteral)

• NICE TA552 Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia

Fludarabine (oral & parenteral)

• NICE TA29 Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia

Fluorouracil (parenteral)

• NICE TA212 Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
• Topical Fluorouracil cream, see Chapter 13

Gemcitabine (parenteral)

• NICE NG85 Guidance on the use of gemcitabine for the treatment of pancreatic cancer
• NICE TA116 Gemcitabine for the treatment of metastatic breast cancer
• NICE NG122 Lung cancer: The diagnosis and treatment of lung cancer
• NICE TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer

Mercaptopurine (oral)

• Also used for Inflammatory Bowel disease – unlicensed indication (TLS amber)

Methotrexate (parenteral)

• TLS Red for malignant conditions

Methotrexate (oral) (TLS Amber 1 month and 3 months)

• TLS Amber for non-malignant conditions:
• See Chapter 1 for Inflammatory bowel disease
• See Chapter 4 for Neuromuscular disorders
• See Chapter 10 for Arthritis
• See Chapter 13 for Dermatology

Glucarpidase

• Clinical Commissioning Policy: Glucarpidase for the urgent treatment of methotrexate-induced renal dysfunction

Nelarabine (parenteral)

• As per Cancer Drugs Fund restrictions

Pemetrexed (parenteral)

• NICE TA135 Pemetrexed for the treatment of malignant pleural mesothelioma
• NICE TA181 Pemetrexed for the first-line treatment of non-small-cell lung cancer. Also see NHS England Circular 1530 for Pemetrexed as maintenance treatment
• NICE TA190 Pemetrexed for the maintenance treatment of non-small-cell lung cancer
• NICE TA402 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin. Funding according to NHS England SCC 1647

Rucaparib

• NICE TA611 for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer

Tegafur / Uracil (oral)

• NICE TA61 guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer

Tioguanine (Thioguanine) (oral)

Antineoplastic Antibiotics

Bleomycin (parenteral)

Bleomycin (IV) electrochemotherapy treatment (TLS Red) 

• For use in combination with reversible electroporation of the spinal tumour for treatment of metastatic spinal cord compression as a palliative treatment option where there are no other available treatment options i.e. surgery is not suitable and have not responded to chemotherapy and radiotherapy
• Restricted to use on the advice of the Oncologist/Spinal Surgeon and Spine MDT only.

Dactinomycin (parenteral)

Mitomycin (parenteral & bladder instillation)

• Also see Chapter 11 Eye

Pentostatin (parenteral)

Platinum Compounds

Carboplatin (parenteral)

Cisplatin (parenteral)

Oxaliplatin (parenteral)

• NICE NG151 Colorectal cancer: The diagnosis and management of colorectal cancer

Podophyllotoxin Derivatives

Etoposide (oral & parenteral)

Etoposide phosphate (parenteral)

• UHB only, for fluid restricted patients

Taxanes

Cabazitaxel (parenteral)

• NICE TA391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel in accordance with NHS England Circular SSC 1627

Docetaxel (parenteral)

• NICE NG101 Breast cancer
• NICE CG81 Advanced breast cancer
• NICE NG122 for NSCLC
• NICE TA101 Prostate cancer
• See NHS England policy B15/PS/a Docetaxel in combination with androgen deprivation therapy for the treatment of hormone naïve metastatic prostate cancer
• NICE TA509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer

Paclitaxel (parenteral)

• NICE TA34 guidance Breast cancer
• NICE TA55 guidance Ovarian cancer
• NICE TA389 guidance Recurrent ovarian cancer
• NICE TA476 guidance Untreated metastatic pancreatic cancer

Topoisomerase I Inhibitors

Irinotecan hydrochloride (parenteral)

• NICE NG151 guidance colorectal cancer

Topotecan (oral)

• NICE TA183 guidance Cervical cancer
• NICE TA184 guidance Small cell lung cancer
• NICE TA389 guidance Recurrent ovarian cancer

Vinca Alkaloids

Vinblastine (parenteral)

Vincristine (parenteral)

Vinorelbine (parenteral)

Other Cytotoxic drugs

Amsacrine (parenteral)

Arsenic trioxide (parenteral)

• Relapsed or refractory acute promyelocytic leukaemia (APML)
• NICE TA526 Arsenic trioxide for treating acute promyelocytic leukaemia

Bexarotene (oral)

Crisantaspase (parenteral)

Eribulin (parenteral)

• NICE TA515 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen

Hydroxycarbamide (oral - capsules) (TLS Amber 3 months)

• To be prescribed generically for all indications
• TLS Amber for stable myeloproliferative disorders only (SCP click here)
• TLS Red for all other conditions

Mitotane (oral)

Procarbazine (oral)

Trabectedin (parenteral)

• NICE TA185 guidance Trabectedin for the treatment of advanced soft tissue sarcoma
• NICE TA389 guidance Recurrent ovarian cancer

Retinoid and Related Drugs

Tretinoin (oral)

8.2.1 Cytotoxic drug-induced side effects

Uroprotective Drugs

Mesna (oral & parenteral) (TLS Green)

Folates

Folinic acid (oral & parenteral) (TLS Green)

8.2.1a Hyperuricaemia

Rasburicase (parenteral)

• Consultant Haematologist / Nephrologist prescription only for patients identified as being at high risk of tumour lysis syndrome, or where standard preventative measures are not possible or have failed
• For guidance on use in haematological malignancies see British Committee for standards in Haematology

Pegaspargase

• NICE TA408 Pegaspargase for treating acute lymphoblastic leukaemia

8.2.3 Hormone responsive malignancy

Anti-Androgens

Bicalutamide (oral) (TLS Amber 1 month) (SCP click here)

Cyproterone (oral) (TLS Amber) (SCP click here)

Abiraterone (oral)

• In accordance with NICE TA259
• In accordance with NICE TA387

Apalutamide

• NICE TA740 Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer
• NICE TA741 Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

Enzalutamide (oral)

• NICE TA316 Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen  
• NICE TA377 Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
• NICE TA712 Enzalutamide for treating hormone-sensitive metastatic prostate cancer

Darolutamide (oral)

• NICE TA660 Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
• NICE TA903 Darolutamide for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel

Oestrogens

Diethylstilbestrol (oral) (TLS Green)

Anti-Gonadotropin-Releasing Hormones

Degarelix (Firmagon^®) (subcutaneous) (TLS Amber 1 month) (SCP Click here)

• NICE TA404 Degarelix for treating advanced hormone-dependent prostate cancer

Somatostatin Analogues

Octreotide (parenteral)

Lanreotide (parenteral)

Pasireotide (subcutaneous)

• In Cushing's disease according to NHS England Commissioning Policy 16052/P

Progestogens 

Medroxyprogesterone acetate (oral) (TLS Green)

Megestrol (oral) (TLS Green)

Norethisterone (oral) (TLS Green)

Gonadotophin-Releasing Hormone Analogues

For detail on GnRH analogues see Chapter 6.6 Gonadotrophin responsive conditions

8.2.4 Hormone responsive breast cancer

Selective Oestrogen Receptor Modulator / Anti-Oestrogen

Tamoxifen (oral) (TLS Amber Specialist Recommended)

• Breast Cancer
  • NICE NG101 Breast cancer Early and locally advanced breast cancer
  • Duration of therapy for cancer treatment is as advised by the oncology specialist team. 
• Risk reduction and prevention of familial breast cancer - NICE CG164
  
  • Chemoprevention: High and moderate risk
  • Duration of therapy for chemoprophylaxis is 5 years.

Aromatase Inhibitors

Anastrozole (oral) (TLS Amber Specialist Recommended)

• Only for people who are post menopausal
• Breast Cancer:
  • Duration of therapy for cancer treatment is as advised by the oncology specialist team. 
• Risk reduction and prevention of familial breast cancer - NICE CG164
  • Chemoprevention: High and moderate risk
  • Duration of therapy for chemoprophylaxis is 5 years.

Exemestane (oral) (TLS Amber Specialist Recommended)

Letrozole (oral) (TLS Amber Specialist Recommended)

Gonadotrophin-Releasing Hormone Analogues

For detail on GnRH analogues see Chapter 6.6 Gonadotrophin responsive conditions

8.2.5 Immunotherapy responsive malignancy

Immunomodulating Drugs

Mifamurtide (parenteral)

• NICE TA235 guidance for the treatment of osteosarcoma

Trifluridine-tipiracil (oral)

• NICE TA405 guidance for previously treated metastatic colorectal cancer
• NICE TA852 Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments

Interferons

Interferon alfa (Roferon-A^®) (parenteral)

Peginterferon alfa (parenteral)

• NICE TA96 Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (partially updated by CG165 Chronic hepatitis B)
• NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
• NICE TA300 Peginterferon alfa and ribavirin for the treatment of chronic Hepatitis C in children and young people
• According to ASWCS protocols

Interferon beta (parenteral)

• As per NHS England Clinical Commissioning Policy: Disease-modifying therapies for patients with multiple sclerosis (D04/P/b)
• NICE TA527 (replaces NICE TA32) Beta interferons and glatiramer acetate for treating multiple sclerosis

Peginterferon beta-1a

• NICE TA624 for treating relapsing–remitting multiple sclerosis

Interleukins

Aldesleukin (parenteral)

Immunotherapies

BCG bladder irrigation (instillation)

Chimeric Antigen Receptor (CAR) T Cell Therapy

Axicabtagene ciloleucel

• NICE TA872 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies as per Cancer Drug Fund
• NICE TA895 Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy

Tisagenlecleucel

• NICE TA554 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years as per Cancer Drug Fund
• NHSE SSC 2585 Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
• NICE 2644 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (MA review of TA554)

Brexucabtagene autoleucel

• NICE TA893 Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over

Thalidomide and Related Analogues

Lenalidomide (oral)

• NICE TA171 Lenalidomide for treatment of multiple myeloma in people who have received at least one prior therapy
• NICE TA587 Lenalidomide plus dexamethasone for previously untreated multiple myeloma
• NICE TA586 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
• NICE TA627 Lenalidomide with rituximab for previously treated follicular lymphoma
• NICE TA680 Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma

Pomalidomide (oral)

• NICE TA427 guidance Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib

Thalidomide (oral) (Celgene^®)

• NICE TA228 guidance for the first-line treatment of multiple myeloma
• Also see local protocols
• For chronic cough associated with idiopathic pulmonary fibrosis

8.2.6 Targeted therapy responsive malignancy

Protein Kinase Inhibitors

Abemaciclib (oral)

• NICE TA563 Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
• NICE TA725 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
• NICE TA810 Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence

Acalabrutinib (oral)

• NICE TA689 Acalabrutinib for treating chronic lymphocytic leukaemia

Afatinib (oral)

• NICE TA310 Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
• NHS England Circular SSC1421

Alectinib (oral)

• NICE TA536 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer

Alpelisib (oral)

• NICE TA816 Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer

Asciminib (oral)

• NICE TA813 Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors

Axitinib (oral)

• NICE TA333 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

Bosutinib (parenteral)

• NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia

Brigatinib (oral)

• NICE TA571 Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
• NICE TA670 Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor

Cabozantinib (oral)

• NICE TA463 Cabozantinib for previously treated advanced renal cell carcinoma (Not on cancer drug fund)
• NICE TA516 Cabozantinib for treating medullary thyroid cancer as per cancer drug fund
• NICE TA542 Cabozantinib for untreated advanced renal cell carcinoma
• NICE TA849 Cabozantinib for previously treated advanced hepatocellular carcinoma
• NICE TA964 Cabozantinib with nivolumab for untreated advanced renal cell carcinoma

Ceritinib (oral)

• NICE TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
• NICE TA500 Ceritinib for untreated ALK-positive non-small-cell lung cancer

Crizotinib (oral)

• NICE TA406 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
• NICE TA422 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
• NICE TA529 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (CDF)

Dabrafenib (parenteral)

• NICE TA321 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
• NICE TA396 In combination with trametinib for treating unresectable or metastatic melanoma
• NICE TA544 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
• NHSE Clinical commissioning policy: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer
• NICE TA898 Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer

Dacomitinib (oral)

• NICE TA595 for untreated EGFR mutation-positive non-small-cell lung cancer and NHS England Circular SCC 2092

Dasatinib (oral)

• NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
• NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia

Encorafenib (oral)

• NICE TA562 Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
• NICE TA668 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

Entrectinib

• NICE TA643 Entrectinib for treating ROS1-positive advanced non-small cell lung cancer
• NICE TA644 Entrectinib for treating NTRK fusion-positive solid tumours

Erlotinib (oral)

• NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
• NICE TA227 Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
• NICE TA258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
• 2nd line treatment of NSCLC in patients unable to receive docetaxel
• 3rd and subsequent line treatment of NSCLC in patients who have previously not received erlotinib
• NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy

Everolimus (oral)

• NICE TA421 guidance Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
• NICE TA432 guidance Everolimus for treating advanced renal cell carcinoma after previous treatment
• NICE TA449 guidance Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
• For angiomyolipomas associated with tuberous sclerosis according to NHS England Clinical Commissioning Policy B14X09L
• For Subependymal Giant cell Astrocytoma associated with tubular sclerosis se NHS England Clinical Commissioning Policy 16066/P

Fedratinib

• NICE TA756 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis

Gefitinib (oral)

• NICE TA192 guidance Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
• NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy

Gilteritinib

• NICE TA642 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia

Ibrutinib (oral)

• NICE TA429 guidance Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (Not on cancer drug fund list)
• NICE TA502 guidance Ibrutinib for treating relapsed or refractory mantle cell lymphoma
• NICE TA795 Ibrutinib for treating Waldenstrom’s macroglobulinaemia
• NICE TA891 Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia 

Idelalisib (oral)

• NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia

Imatinib (oral)

• NICE TA70 Chronic myeloid leukaemia
• NICE TA86 Treatment of unresectable and/or metastatic gastrointestinal stromal tumours
• NICE TA326 Adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196) as per NHS England Circular 1568
• Treatment of patients with newly diagnosed Ph+ acute lymphoblastic Leukaemia
• NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
• NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia

Ivosidenib

• NICE TA948 Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments

Larotrectinib

• NICE TA630 Larotrectinib for treating NTRK fusion-positive solid tumours

Lenvatinib

• NICE TA535 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
• NICE TA551 Lenvatinib for untreated advanced hepatocellular carcinoma
• NICE TA858 Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma

Lenvatinib with Everolimus (oral)

• NICE TA498 Lenvatinib with Everolimus for previously treated advanced renal cell carcinoma

Lorlatinib

• NICE TA628 Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

Midostaurin (oral)

• NICE TA523 Midostaurin for untreated acute myeloid leukaemia
• NICE TA728 Midostaurin for treating advanced systemic mastocytosis

Mobocertinib (oral)

• NICE TA855 Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

Momelotinib

• NICE TA957 Momelotinib for treating myelofibrosis-related splenomegaly or symptoms

Neratinib (oral)

• NICE TA612 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab

Nilotinib (oral)

• NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
• NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia

Osimertinib (oral)

• NICE TA653 Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
• NICE TA654 Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
• NICE TA761 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Palbociclib (oral)

• NICE TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer as per cancer drug fund
• NICE TA836 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Pazopanib (oral)

• NICE TA215 Pazopanib for the first-line treatment of advanced renal cell carcinoma

Pemigatinib (oral)

• NICE TA722 Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement

Ponatinib (oral)

• NICE TA451 guidance for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia

Ribociclib (oral)

• NICE TA496 Ribociclib with an aromatase inhibitor for treating previous untreated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer as per cancer drug fund
• NICE TA687 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Regorafenib (oral)

• NICE TA488 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
• NICE TA555 Regorafenib for previously treated advanced hepatocellular carcinoma
• NICE TA866 Regorafenib for previously treated metastatic colorectal cancer

Ruxolitinib (oral)

• NICE TA386 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
• NICE TA921 Ruxolitinib for treating polycythaemia vera

Selpercatinib

• NICE TA742 Selpercatinib for treating advanced thyroid cancer with RET alterations
• NICE TA760 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
• NICE TA911 Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer

Sorafenib (oral)

• NICE TA474 guidance Sorafenib for treating advanced hepatocellular carcinoma
• NICE TA535 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
• NHSE SSC 2588 Sorafenib maintenance for adults with FLT3-internal tandem duplication (FLT3-ITD) acute myeloid leukaemia (AML) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT)

Sunitinib (oral)

• NICE TA169 Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
• NICE TA179 Sunitinib for the treatment of gastrointestinal stromal tumours
• NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease

Talimogene laherparepvec (parenteral)

• NICE TA410 Talimogene laherparepvec for treating unresectable metastatic melanoma

Temsirolimus (parenteral)

Tepotinib

• NICE TA789 Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations

Tivozanib (oral)

• NICE TA512 Tivozanib for treating advanced renal cell carcinoma

Trametinib (oral)

• NICE TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma

Tucatinib (oral)

• NICE TA786 Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies

Vandetanib (oral)

• Cancer Drugs Fund restrictions

Vemurafenib (oral)

• NICE TA269 guidance Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma

Zanubrutinib (oral)

• NICE TA833 Zanubrutinib for treating Waldenstrom’s macroglobulinaemia
• NICE TA931 Zanubrutinib for treating chronic lymphocytic leukaemia

Antifibrotics

Nintedanib (oral)

• NICE TA347 guidance Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer
• NICE TA379 Nintedanib for treating idiopathic pulmonary fibrosis

Proteasome Inhibitors

Bortezomib (parenteral)

• As per Cancer Drugs Fund restrictions
• NICE TA129 guidance Bortezomib monotherapy for relapsed multiple myeloma
• NICE TA228 guidance Multiple Myeloma in combination with an alkylating agent and a corticosteroid
• NICE TA311 guidance Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
• 1st line treatment of multiple myeloma in patients who are not NICE eligible for Bortezomib due to presentation with a) advanced renal failure contraindicating standard therapy (dialysis either current or imminent) or b) multisystem amyloidosis (on amyloid centre review)
• 1st line treatment of multiple myeloma in patients for who transplant is considered unsuitable
• NICE TA370 Bortezomib for previously untreated mantle cell lymphoma

Carfilzomib

• NICE TA657 Carfilzomib for previously treated multiple myeloma
• NICE TA695 Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma

Ixazomib with Lenalidomide and Dexamethasone

• NICE TA870 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma as per Cancer Drug Fund

Hedgehog Pathway Inhibitors

Vismodegib (oral)

• NICE TA489 Vismodegib for treating basal cell carcinoma

KRAS Inhibitors

Sotorasib (oral)

• NICE TA781 Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

Selective Internal Radiation

Selective Internal Radiation Therapies

• NICE TA688 Selective internal radiation therapies for treating hepatocellular carcinoma

PARP Inhibitors

Niraparib (oral)

• NICE TA673 Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
• NICE TA784 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

Olaparib

• NICE TA962 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
• NICE TA946 Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer
• NICE TA886 Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
• NICE TA887 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
• NICE TA908 Olaparib for maintenance treatment of relapsed, platinum-sensitive, ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
• NICE TA951 Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer 
• NICE TA946 Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer

Note: Tablets are NOT interchangeable with capsules due to bioavailability issues.

Talazoparib

• NICE TA952 Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations

Selective Inhibitor of Nuclear Transport

Selinexor

• NHSE SSC 2613 Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma
• NHSE SSC 2641 Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
• NHSE SCC 2648 Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma

Other

Autologous anti-CD19-transduced CD3+ cells

• NICE TA677 Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma

Chlormethine gel

• NICE TA720 Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma

Panobinostat (oral)

• NICE TA380 Panobinostat for treating multiple myeloma after at least 2 previous treatments
• As per NHS England SSC 1606

Talimogene (parenteral)

• NICE TA410 Talimogene laherparepvec for treating unresectable metastatic melanoma. Via NHS England funding as per SSC 1642

Venetoclax (oral)

• NICE TA561 Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
• NICE TA663 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
• NICE TA765 Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
• NICE TA787 Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
• NICE TA796 Venetoclax for treating chronic lymphocytic leukaemia

Contact Us

Got a question or comment about the Joint Formulary? 

Please use the email address below to contact us and we will endeavour to respond within 2 working days.